What is the mechanism of action of Lecanemab at the neuronal and cellular level in treating Alzheimer's disease?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18203525
Cited by: 0

Abstract

Lecanemab acts by binding to soluble amyloid-beta protofibrils, reducing amyloid plaques and neurotoxicity, potentially slowing Alzheimer's progression in early disease stages.

Fields of Study & Subjects

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Neuroinflammation and Neurodegeneration Mechanisms

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
9 January 2026